Investigating Chemobrain onset: A pilot study exploring the severity and onset of cognitive impairment
Review TypeAbstract Review Only: Reviewed by Event Host
Review StatusNot Applicable (See Review Type)
Repository Posting Date2019-07-05T14:12:18Z
Author DetailsKelly Moore, BSN, RN, OCN, email: Kelly2.Moore@UTSouthwestern.edu. Ms. Moore has been a Registered Nurse since 2010. Since then she has worked with oncology patients in the capacity as a bedside nurse, infusion nurse, and as a nurse manager. She is a member of the American Nurses Association, Texas Nurses Association, and Oncology Nurses Association. She served as the Principal Investigator of The Chemobrain Study, which was a multi-center study that was funded by the J. Patrick Barnes research grant. Daiwai Olson, PhD, RN, CCRN, email: Daiwai.Olson@UTSouthwestern.edu.
Lead Author Sigma AffliationNon-member
Lead Author AffliationThe University of Texas Southwestern Medical Center
Level of EvidenceObservational
Research ApproachPilot/Exploratory Study
CINAHL HeadingsCognition--Drug Effects; Chemotherapy, Cancer--Adverse Effects; Oncologic Nursing; Cognition; Chemotherapy, Cancer
Background: Chemotherapy related changes in cognition fall into a cluster of symptoms commonly referred to as chemobrain. To date, nursing literature on the progression of chemobrain and tools used to describe this progression are scant. Objectives: The purpose of this pilot study was to explore the onset of chemobrain in persons who recently began chemotherapy and those who have been undergoing therapy for a longer period of time. Methods: This was a prospective, non-randomized, observational, pilot feasibility study of adult chemotherapy patients pilot that aimed to provide a foundation into nursing research examining cognitive changes associated with chemotherapy. Findings: Of 50 subjects enrolled 16 had lower scores at follow-up and 14 had improved scores comparing baseline and follow-up. According to the Trail Making A&B testing, 49 of 50 patients fell in the healthy range of cognitive functioning. Paired t-tests showed significant differences in baseline and 8-month Trail Making A scores (p<0.05), and comparing 4 and 8-month Trail Making B score (p<0.05). The mixed results suggest that Trail Making A & B may not be appropriate tests for chemotherapy associated cognitive decline in patients (chemobrain).
Funder(s)The Daisy Foundation
DescriptionThe research study is completed. At the time of submission to this repository, a manuscript was under review with the Clinical Journal of Oncology Nursing.
Conference NameOncology Nursing Society
Conference HostOncology Nursing Society
Conference LocationAnaheim, California, USA
Visits vs Downloads
Visitors - World Map
Top Visiting Countries
Top Visiting Cities
Visits (last 6 months)
Downloads (last 6 months)
Popular Works for Moore, Kelly by View
Popular Works for Moore, Kelly by Download